Hanks G E, D'Amico A, Epstein B E, Schultheiss T E
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111.
Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):125-7. doi: 10.1016/0360-3016(93)90429-y.
This study was undertaken to investigate the relationship of prostatic specific antigen doubling time with disease progression in irradiated patients whose only sign of failure was an abnormal prostatic specific antigen.
Post irradiation patients whose only sign of failure was an elevated prostatic specific antigen were followed without treatment. The prostatic specific antigen doubling time was determined and compared to original characteristics of disease, time to elevation of prostatic specific antigen after treatment and time to a second sign of failure.
The prostatic specific antigen doubling times varied from 1.2 months to 36 months. The original grade and stage correlated with the doubling time as did the intervals to elevation of prostatic specific antigen and to a second sign of failure.
We recommended delaying intervention until the prostatic antigen doubling time can be calculated for patients with prostatic specific antigen elevation as the only sign of failure. Patients with short doubling times (< 9 months) can be promptly treated while those with longer doubling times (> 1 year) may have androgen suppression delayed avoiding the cost and morbidity of that treatment.
本研究旨在调查仅以前列腺特异性抗原异常作为失败标志的接受放疗患者中前列腺特异性抗原倍增时间与疾病进展的关系。
对仅以前列腺特异性抗原升高作为失败标志的放疗后患者进行随访，不进行治疗。测定前列腺特异性抗原倍增时间，并与疾病的原始特征、治疗后前列腺特异性抗原升高的时间以及出现第二个失败标志的时间进行比较。
前列腺特异性抗原倍增时间从1.2个月到36个月不等。疾病的原始分级和分期与倍增时间相关，前列腺特异性抗原升高的间隔时间以及出现第二个失败标志的间隔时间也与倍增时间相关。
我们建议对于仅以前列腺特异性抗原升高作为失败标志的患者，在能够计算出前列腺抗原倍增时间之前推迟干预。倍增时间短（<9个月）的患者可立即接受治疗，而倍增时间长（>1年）的患者可推迟雄激素抑制治疗，避免该治疗的费用和并发症。
